These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 32796360)

  • 61. Cutoff values of protein induced by vitamin K absence or antagonist II for diagnosing hepatocellular carcinoma.
    Jang TY; Dai CY
    Medicine (Baltimore); 2022 Sep; 101(39):e30936. PubMed ID: 36181046
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Measurement of des-gamma-carboxy prothrombin levels in hemodialysis patients positive for anti-hepatitis virus C antibody.
    Kato A; Yasuda H; Togawa A; Yamamoto T; Yonemura K; Maruyama T; Maruyama Y; Hishida A
    Clin Nephrol; 2002 Oct; 58(4):296-300. PubMed ID: 12400845
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.
    Nanashima A; Taura N; Abo T; Ichikawa T; Sakamoto I; Nagayasu T; Nakao K
    Dig Dis Sci; 2011 Oct; 56(10):3086-100. PubMed ID: 21706206
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
    Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
    Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma.
    Wang X; Zhang W; Liu Y; Gong W; Sun P; Kong X; Yang M; Wang Z
    Infect Agent Cancer; 2017; 12():47. PubMed ID: 28852419
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients.
    Saitta C; Raffa G; Alibrandi A; Brancatelli S; Lombardo D; Tripodi G; Raimondo G; Pollicino T
    Medicine (Baltimore); 2017 Jun; 96(26):e7266. PubMed ID: 28658121
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
    Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.
    Abdel-Razik A; Elhelaly R; Elzehery R; El-Diasty A; Abed S; Elhammady D; Tawfik A
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):599-605. PubMed ID: 26741637
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP.
    Baek YH; Lee JH; Jang JS; Lee SW; Han JY; Jeong JS; Choi JC; Kim HY; Han SY
    Hepatogastroenterology; 2009; 56(91-92):763-7. PubMed ID: 19621698
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
    Morota K; Nakagawa M; Sekiya R; Hemken PM; Sokoll LJ; Elliott D; Chan DW; Dowell BL
    Clin Chem Lab Med; 2011 Apr; 49(4):711-8. PubMed ID: 21231906
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Longitudinal surveillance of three biomarkers to predict recurrence of hepatocellular carcinoma after radical resection.
    Tong JS; Lu CD; Lu CJ; Zheng S; Mao SQ
    Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1178-1185. PubMed ID: 37577836
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Predictive value of PIVKA-II and AFP for the non-objective response of HBV-associated hepatocellular carcinoma after transarterial chemoembolization: a prospective study.
    Wang L; Yang X; Wang J; Yu G
    Eur J Gastroenterol Hepatol; 2023 Dec; 35(12):1410-1415. PubMed ID: 37942758
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PIVKA-II combined with alpha-fetoprotein for the diagnostic value of hepatic tumors in children: a multicenter, prospective observational study.
    Gao H; Xie C; Wang J; Ma J; Liu S; Xie L; Zheng Y; Dong R; Wang S; Fang Y; Wu Y; Zhang X; Lu X; Li Y; Li W; Pan Q; Xu M; Gu S
    Hepatol Int; 2024 Aug; 18(4):1326-1335. PubMed ID: 38622445
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma.
    Fujioka M; Nakashima Y; Nakashima O; Kojiro M
    Hepatology; 2001 Dec; 34(6):1128-34. PubMed ID: 11732002
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar.
    Taketa K; Okada S; Win N; Hlaing NK; Wind KM
    Acta Med Okayama; 2002 Dec; 56(6):317-20. PubMed ID: 12685861
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Stereotactic radiotherapy for hepatocellular carcinoma induced by hepatitis C and the relationships of changes in carbohydrate antigen 19-9 with AFP and PIVKA-II.
    Maebayashi T; Ishibashi N; Aizawa T; Sakaguchi M; Okada M
    Cancer Radiother; 2021 May; 25(3):242-248. PubMed ID: 33455875
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Diagnostic performance of PIVKA-II in identifying recurrent hepatocellular carcinoma following curative resection: a retrospective cohort study.
    Zhu W; Wang W; Zheng W; Chen X; Wang X; Xie J; Jiang S; Chen H; Zhu S; Xue P; Jiang X; Li H; Wang G
    Sci Rep; 2024 Apr; 14(1):8416. PubMed ID: 38600210
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma.
    Villalba-López F; Sáenz-Mateos LF; Sánchez-Lorencio MI; De La Orden-García V; Alconchel-Gago F; Cascales-Campos PA; García-Bernardo C; Noguera-Velasco JA; Baroja-Mazo A; Ramírez-Romero P
    Sci Rep; 2023 Apr; 13(1):5621. PubMed ID: 37024609
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of PIVKA-II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery.
    Cai Y; Xie K; Adeeb Alhmoud MN; Lan T; Wan H; Hu D; Lan L; Liu C; Wu H
    Cancer Med; 2023 Sep; 12(17):17866-17877. PubMed ID: 37596739
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection.
    Gentile I; Buonomo AR; Scotto R; Zappulo E; Carriero C; Piccirillo M; Izzo F; Rizzo M; Cerasuolo D; Borgia G; Cavalcanti E
    In Vivo; 2017; 31(4):695-700. PubMed ID: 28652441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.